Omnicare and CVS Settle False Claims Act Case for $440M
Omnicare LLC and CVS Health will pay $440 million to settle an FCA lawsuit.
Why it matters: Large False Claims Act settlements like this one underscore the high financial and reputational risks healthcare companies face. In-house legal teams and law firms must prioritize compliance and risk management to avoid similar liabilities.
- Settlement announced July 1, 2026, resolving a decade-long False Claims Act lawsuit.
- Omnicare to pay at least $310 million from its bankruptcy estate; CVS to pay $130 million up front.
- The lawsuit alleged Omnicare dispensed drugs without valid prescriptions and submitted false claims to federal programs.
- The total judgment in April 2025 was approximately $948.8 million, trebled from $135.6 million original damages.
On July 1, 2026, Omnicare LLC and its parent company, CVS Health Corporation, disclosed a $440 million settlement agreement with the Department of Justice to resolve a False Claims Act (FCA) lawsuit. The settlement addresses allegations that Omnicare dispensed prescription drugs to long-term care residents without valid prescriptions and submitted fraudulent claims for reimbursement to federal healthcare programs.
CVS will pay $130 million up front, while Omnicare’s bankruptcy estate will contribute a minimum of $310 million. Omnicare filed for Chapter 11 bankruptcy in September 2025 following a jury verdict that found the company liable under the FCA with a judgment stemming from $135.6 million in initial damages, trebled to $406.8 million, plus statutory penalties totaling approximately $948.8 million.
The settlement is subject to approval by the United States Bankruptcy Court for the Northern District of Texas, with a hearing scheduled for August 12, 2026. CVS spokespersons stated the settlement is not an admission of liability but an effort to avoid further litigation costs and to move beyond the chapter 11 case.
Earlier, CVS was found jointly and severally liable for $164.8 million of the statutory penalties. Omnicare’s business was sold in May 2026 to GenieRx Holdings LLC for $250 million after the bankruptcy filing.
This case highlights the serious consequences of compliance failures in the healthcare sector and serves as a reminder that legal teams must vigilantly manage fraud risks and regulatory obligations related to pharmaceutical services.
By the numbers:
- $440 million — total settlement amount between Omnicare, CVS, and DOJ
- $948.8 million — April 2025 total FCA judgment including trebled damages and penalties
- $130 million — up-front payment by CVS as part of the settlement
Yes, but: The settlement does not include specific public disclosures on changes to internal compliance programs at Omnicare or CVS, leaving the practical impact to corporate governance uncertain.
What's next: The bankruptcy court hearing on August 12, 2026, will decide whether to approve the settlement agreement.